Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B
Crossref DOI link: https://doi.org/10.1186/s40169-016-0111-8
Published Online: 2016-08-18
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Malecki, Marek
Sabo, Chelsea
Foorohar, Afsoon
Tombokan, Xenia
Funding for this research was provided by:
PBMEF (2006070101)
National Science Foundation (9420056, 9522771, 9902020, 0094016)
National Institutes of Health (P41 RR000570, P41 RR002301)
Accepted Manuscript valid from 2016-08-18
Version of Record valid from 2016-08-18
License valid from 2016-08-18